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After 20 Years, Liver Transplantation Comes of Age 
AFTER 20 YEARS as an experimental procedure. ortho-
topic liver transplantation for patients with advanced he-
patic disease has come of age (i, 2). Survival statistics 
from the four centers with the most experience suggest 
that the i-year survival for children having a hepatic 
transplant should exceed 70%, whereas that for adults 
should exceed 50% and may, with more care given to the 
choice of candidates and experience, approach the level 
of success being achieved in children (3-7). Late deaths 
among transplant recipients occurring after the first year 
of survival are unusual and attrition after 1 year of sur-
vival actually approaches that seen in the general popula-
tion (2). The longest known living hepatic transplant 
survivor is alive, 15 years after the original procedure. 
Encouraged by these results. several hepatic transplan-
tation programs have been started or reopened_ In the 
United States. in addition to the program at the Universi-
ty of Pittsburgh, liver transplantation prognlms presently 
exist at the University of Minnesota, the University of 
Tennessee, the University of California (Davis), Harvard 
University (Massachusetts General Hospital), and Tufts 
University. Additional programs are likely to develop at 
sever~l other university health centers. inciuding the Uni-
versity of California (San Diego), University of Wiscon-
sin, and the Medical College of Virginia, and in Toronto 
and, Montreal in Canada. Abroad, active programs al-
ready exist in Cambridge, England, and in Holland, East 
Germany, and West Germany; others are being devel-$e 
oped in London, England, and in France, Spain. Italy, i:'_.' .:,
China, and Taiwan_ 
Two factors have contributed to the recent success of 4 
orthotopic liver transplantation: the availability and use i: 
of cyclosporine; and the joint involvement of medical and r 
surgical teams in the evaluation, selection, and pre- and 
postoperative care of hepatic transplant patients. f 
The discovery of cyclosporine, a potent immunosup- ~ 
pressive agent having little or no bone marrow toxicity, ,. 
has revolutionized not only hepatic but all forms of im- ! 
munosuppression therapy used for organ transplantation ,' •. ", 
(8-13). Its development was particularly important be- r.> 
cause of the time constraints of liver preservation, the ~: 
recipient's urgent need for the procedure. and the abso-
lute unavailability of living related donors. Moreover, 
matching donors and recipients at the HLA, A, B, and .. , 
Dr loci of the recognized histocompatibility antigens has 
been impractical beCause of the iimited number of donor 
organs available. Similarly, the neCessity for a patient to 
receive a transplant despite anti-donor T warm antibod-
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ies will persist because of the limited number of donor 
organs available and the urgent need to do the transplant 
in a given candidate (2). These difficulties can be avoided 
in renal transplantation because of the larger pool of do-
nor organs (two from each cadaver and one from each 
living related donor). the existence of an acceptable alter-
native renal support system (peritoneal and hemodialy-
sis). and the cold ischemia time tolerated by the kidney 
to be transplanted that allows for successful engraftment 
in a recipient thousands of miles and hours away from 
the donor. 
In addition to time constraints and an overall lack of 
donor organs. another problem that limits transplanta-
tion teams from better matching donors and recipients is 
the need to have a donor organ smaller than that of the 
recipient. so that it can physically be implanted and the 
abdominal wound closed (2). Thus the use of HLA and 
other means of matching donors and recipients is not 
available for liver transplantation. As a result, more pow-
erful immunosuppressant agents such as cyclosporine are, 
required for successful hepatic transplantation than are 
required for nonhepatic organs. 
The second factor has been the commitment of experi-
enced and independent hepatologists working with hepat-
ic surgeons in the several largest transplant programs 
(14). Thus both at Cambridge and Pittsburgh, hepatolo-
gists as well as surgeons are involved in the liver trans-
plant program. Such cooperation and interaction between 
disciplines has contributed to a better selection of trans-
plant candidates and the earlier recognition and manage-
ment of postoperative complications such as sepsis. rejec-
tion. and liver failure (14. IS). Equally important is the 
identification of patients with better and poorer prognos-
es after hepatic transplantation. and of the clinical situa-
tions that predict operative or postoperative difficulty 
(such as portal vein thrombosis. presence of coexisting 
non hepatic medical and surgical disease. the presence of 
biliary or extrahepatic sepsis, and hepatitis B surface and 
e antigenemia) (15). 
More important than simple survival statistics is the 
quality of life of patients after successful liver transplan-
tation. Few data are available that address this issue 
(15). Anecdotal information shows that successful preg-
nancy and parenthood is possible after liver transplanta-
tion; a return to active life and gainful employment is 
achieved in as many as 85% of adults receiving trans-
plants; and children who have successful transplants re-
turn to school and have normal growth and pubertal de-
velopment. 
The National Institutes of Health recently held a con-
sensus conference in Bethesda. Maryland. on liver trans-
plantation. After a thorough evaluation of the data pre-
sented by experts in liver disease both from the United 
States and abroad. the conference panel concluded that 
orthotopic liver transplantation is therapeutic for some 
forms of chronic advanced liver disease and should be 
more broadly applied; should undergo continuing evalua-
tion; and should be done at a limited number of medical 
centers that have adequate support facilities and a trained 
staft"; and that continued education of physicians who can 
recognize and treat liver diseases. and surgeons who are 
capable of doing the procedure. should be encouraged. 
The important issues of the cost and payment of the 
procedure were not addressed by the panel. However. 
these matters will be addressed by the Office of Health 
Technology Assessment as part of its upcoming reim-
bursement recommendations due in late August 1983. 
Costs of the procedure can differ. At the University of 
Pittsburgh, for example. costs from initial evaluation to 
discharge from hospital after transplantation is between 
$SS 000 to $85 000. depending on the duration of time 
spent in the intensive care unit after the operation (14). 
In contrast. the units at the University of Minnesota and 
in Massachusetts have estimated the cost of the proce-
dure in their areas to range between $200 000 and 
$250000 per patient (16). 
However; the cost of each procedure will tend to de-
cline as the number done increases (which may explain. 
in part. the differences in estimated costs at various loca-
tions in the United States). Also, with increasing experi-
ence at a given institution. the entire process of patient 
selection. operative procedure. and postoperative care be-
comes standardized and more efficient. Series data on iiv-
er transplantation rather than isolated anecdotal infor-
mation are becoming available that will serve as the basis 
on which modifications of existing programs and new 
programs can build.' 
Available data strongly suggest that groups that do the 
procedure with some regularity tend to have the best re-
sults (3-7). This result reflects the natural course of 
events with any new operative procedure. Clinical deci-
sion making is enhanced and patient care improved as 
onc's experience expands. 
The development of a well planned registry of liver 
transplantation procedures should be encouraged and de~ 
veloped. Such a registry would maximize data collection 
on liver transplantation and Serve to crystallize our un-
derstanding of this expanding area of interdisciplinary 
clinical experience. In addition. the registry would facili-
tate the development of protocols for the broader applica-
tion of liver transplantation to patients with hepatic con-
ditions not yet deemed appropriate for the procedure. 
Clearly, a central depository for such data at an active 
liver transplantation center would lead to the most effi-
cient expansion of new ideas and iriformation on tech-
niques. indications, and survival statistics associated with 
liver transplantation. 
Ftnally. the liven of recipients, removed during trans-
plantation. are a unique and valuable resource that 
should .be made available to qualified investigators for 
research directed toward a better understanding of liver 
diseases. hepatic physiology. and human biochemistry in 
general. Thus. effort expended to save these organs and 
make them available to a wide spectrum of investigators 
interested in human disease not only best serves our pa-
tients but also serves society at large. (DAVID H. V AN 
THIEL, M.D.; ROBERT R. SCHADE. M.D.; and THOMAS E. 
STARZL. M.D •• PH.D.; University of Pittsburgh School of 
Medicine; Pittsburgh, Pennsylvania) 
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New Goals for Education in Geriatric Medicine 
How CAN PHYSICIANS be prepared to fulfill the hea1th-
care needs of older persons in the community, in the hos-
pital, and in the long-term care institution? The Execu~ 
tive Council of the Association of American Medical Col-
leges has recently published a set of guidelines by which 
medical colleges can measure their educational efforts in 
geriatric medicine (1). These guidelines represent the 
wisdom of persons representing " ... almost 90 percent of 
the nation's academic medical centers" (1) and provide 
an outline of the breadth of issues and domains of knowl-
edge relevant to care of the elderly. The recommenda-
tions extend those of the Institute of Medicine's report on 
geriatric medical education published 5 years ago (2) 
and certainly will serve as a resource for academic pro-
grams in geriatric medicine. 
Up to now, training in geriatric medicine, in general, 
has used intuitively derived learning objectives, and the 
Associaton's guidelines restate the prevailing trinity of 
geriatric medicine: attitude (poor attitudes to old persons 
compromise their care), demography (the grpwing num-
bers of old persons define the need for geriatric medi-
cine), and leadership (physicians must learn to direct the 
geriatric health-care team). This dogma should be fur-
ther examined. 
The Association's report addresses the need to ensure 
the development of proper attitudes toward the elderly by 
physicians. Studies show that the relation between thera-
pist and patient is critically important to successful care 
(3). However, are positive attitudes more important in 
the care of old patients than they are in the care of 
younger patients? Perhaps of greater relevance, geriatric 
medical education may assert a balance between caring 
and curing in medical education. Furthermore, the new 
report properly emphasizes the different spectrum of dis-
eases,.the frequency of multiple diseases, the altered pre-
sentation of disease, and particularly, the need to extend 
our knowledge of the pathogeneses of the diseases of ag-
ing. 
A frequently repeated raison d'etre for geriatrics is the 
demographic imperative. Today, 11% of Americans are 
over 65 years of age and this percentage will rise as we 
enter the 21st century. Geriatrics has been justified not 
only by the growing age of the population, but because 
the elderly occupy nearly half of the beds in acute care 
hospitals and 86% of beds in long-term care institutions. 
More important than the numbers, however, is the fact 
that geriatricians deal with chronic illness. Chronic dis-
eases are the challenge for medicine in the coming years. 
Geriatric medicine heralds the health care of the 21st 
century, much as Garrod, at the tum of the 20th century, 
recognized the seminal importance of the inborn errors of 
metabolism that foreshadowed the revolution in the mo-
lecular basis of human disease. Geriatrics is concerned 
with patients with mUltiple and chronic diseases that re-
quire continuing care. Today, most of our patients, old 
and young, have chronic diseases. This fact and the need 
to view chronic disease within the perspective of a life 
span and in its interaction with aging physiological sys-
tems are perhaps the most important lessons being 
learned from geriatrics. 
Chronically and mUltiply impaired elderly patients 
need services beyond the realm of traditional medical 
practice. For this reason, the concept of a team (includ-
ing physicians, nurses, social workers, nutritionists, po-
diatrists, and others) that together cares for the patient 
has emerged. The physician-the professional with the 
greatest training and most clout in the health profes-
sions-has been nominated by some, usually physicians, 
to be team leader or case manager. The report by the 
Association of American Medical Colleges suggests pre-
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